Jeff B. Smaill

4.5k total citations
95 papers, 3.4k citations indexed

About

Jeff B. Smaill is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Jeff B. Smaill has authored 95 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Molecular Biology, 28 papers in Cancer Research and 27 papers in Oncology. Recurrent topics in Jeff B. Smaill's work include Cancer, Hypoxia, and Metabolism (28 papers), Cancer Research and Treatments (20 papers) and Lung Cancer Treatments and Mutations (16 papers). Jeff B. Smaill is often cited by papers focused on Cancer, Hypoxia, and Metabolism (28 papers), Cancer Research and Treatments (20 papers) and Lung Cancer Treatments and Mutations (16 papers). Jeff B. Smaill collaborates with scholars based in New Zealand, China and United States. Jeff B. Smaill's co-authors include Adam V. Patterson, Ke Ding, Xiaoyun Lu, William A. Denny, Alexandra M. Mowday, Ian Paterson, David F. Ackerley, Kap‐Sun Yeung, Christopher P. Guise and Ellen M. Dobrusin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Jeff B. Smaill

94 papers receiving 3.3k citations

Peers

Jeff B. Smaill
Uwe Rix United States
Dajun Yang China
Angelika M. Burger United States
Peter Traxler Switzerland
Judy Lucas United States
Kathryn Packman United States
Wilbur R. Leopold United States
Marzia Pennati Italy
Jacques Dumas United States
Steven W. Elmore United States
Uwe Rix United States
Jeff B. Smaill
Citations per year, relative to Jeff B. Smaill Jeff B. Smaill (= 1×) peers Uwe Rix

Countries citing papers authored by Jeff B. Smaill

Since Specialization
Citations

This map shows the geographic impact of Jeff B. Smaill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff B. Smaill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff B. Smaill more than expected).

Fields of papers citing papers by Jeff B. Smaill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff B. Smaill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff B. Smaill. The network helps show where Jeff B. Smaill may publish in the future.

Co-authorship network of co-authors of Jeff B. Smaill

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff B. Smaill. A scholar is included among the top collaborators of Jeff B. Smaill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff B. Smaill. Jeff B. Smaill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ling, Yan, Xiaojuan Song, Zhang Lin, et al.. (2025). Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance. Journal of Medicinal Chemistry. 68(18). 19415–19437. 1 indexed citations
3.
Xu, Fang, Xin Zhang, Zhipeng Chen, et al.. (2022). Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells. Journal of Medicinal Chemistry. 65(20). 14032–14048. 28 indexed citations
4.
Ashoorzadeh, Amir, Alexandra M. Mowday, Christopher P. Guise, et al.. (2022). Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications. Pharmaceuticals. 15(2). 185–185. 3 indexed citations
5.
Liu, Emily, Amir Ashoorzadeh, Gib Bogle, et al.. (2022). Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling. Frontiers in Pharmacology. 13. 803602–803602. 3 indexed citations
6.
Lu, Xiaoyun, Jeff B. Smaill, Adam V. Patterson, & Ke Ding. (2021). Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors. Journal of Medicinal Chemistry. 65(1). 58–83. 91 indexed citations
7.
Chen, Xiaojuan, Xiaojuan Song, Minhao Huang, et al.. (2021). Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. ACS Medicinal Chemistry Letters. 12(4). 647–652. 14 indexed citations
8.
Smaill, Jeff B., et al.. (2020). Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. Journal of Medicinal Chemistry. 63(23). 14404–14424. 68 indexed citations
9.
Lu, Xiaoyun, Jeff B. Smaill, & Ke Ding. (2020). Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. Journal of Medicinal Chemistry. 63(19). 10726–10741. 40 indexed citations
10.
Mowday, Alexandra M., Janine N. Copp, Sophie P. Syddall, et al.. (2020). E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications. Theranostics. 10(23). 10548–10562. 21 indexed citations
11.
Yosaatmadja, Y., Martin Middleditch, Zhen Zhang, et al.. (2019). Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. ACS Medicinal Chemistry Letters. 10(8). 1180–1186. 22 indexed citations
12.
Lu, Xiaoyun, Jeff B. Smaill, & Ke Ding. (2019). Allosterische Kinaseinhibitoren – Erwartungen und Chancen. Angewandte Chemie. 132(33). 13868–13881. 2 indexed citations
13.
Lu, Xiaoyun, et al.. (2018). Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. Journal of Medicinal Chemistry. 62(6). 2905–2915. 60 indexed citations
14.
15.
Zhang, Zhang, Christopher P. Guise, Xueqiang Li, et al.. (2017). 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Medicinal Chemistry Letters. 8(5). 543–548. 34 indexed citations
16.
Han, Kun, Rong Qu, Linjiang Tong, et al.. (2015). 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFRL858R/T790M. Bioorganic & Medicinal Chemistry Letters. 25(19). 4277–4281. 20 indexed citations
17.
Gu, Yongchuan, Frederik B. Pruijn, Jeff B. Smaill, et al.. (2013). Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence. Journal of Biological Chemistry. 288(52). 37138–37153. 18 indexed citations
18.
Smaill, Jeff B., Ho H. Lee, Brian D. Palmer, et al.. (2008). Synthesis and structure–activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases. Bioorganic & Medicinal Chemistry Letters. 18(3). 929–933. 28 indexed citations
19.
20.
Fry, David W., Alexander J. Bridges, William A. Denny, et al.. (1998). Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proceedings of the National Academy of Sciences. 95(20). 12022–12027. 344 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Uwe Rix Breakdown of academic impact, for papers by Dajun Yang Breakdown of academic impact, for papers by Angelika M. Burger Breakdown of academic impact, for papers by Peter Traxler Breakdown of academic impact, for papers by Judy Lucas Breakdown of academic impact, for papers by Kathryn Packman Breakdown of academic impact, for papers by Wilbur R. Leopold Breakdown of academic impact, for papers by Marzia Pennati Breakdown of academic impact, for papers by Jacques Dumas Breakdown of academic impact, for papers by Steven W. Elmore
Rankless by CCL
2026